Samantha McLemore - Patient Capital Management Holdings – 2025 Q4
Explore the latest portfolio disclosure for Samantha McLemore - Patient Capital Management, with insights into sector exposure, position sizes, and overall investment structure for 2025 Q4.
The latest 2025 Q4 filing shows that Samantha McLemore - Patient Capital Management maintains its largest exposure in Unclassified Sector, which represents approximately 22.89% of the portfolio. This sector forms the core of Samantha McLemore - Patient Capital Management's investment stance during this reporting period.
Additional major allocations include Healthcare (about 18.23%) and Technology (approximately 15.95%) , reflecting how Samantha McLemore - Patient Capital Management diversifies beyond its primary sector focus.
These sector weightings provide a clear view into Samantha McLemore - Patient Capital Management's positioning and conviction areas for the 2025 Q4 quarter.
Breakdown by Sector
| Symbol | Shares | Reported Price(USD) | Action | Change % | Portfolio Weight | Position Value | Filing Period |
|---|---|---|---|---|---|---|---|
| GOOGL | 581,637 | $313 | Reduced | -5.17% | 7.03% | $182.05M | 2025 Q4 |
| C | 1,291,794 | $116.69 | Reduced | -1.42% | 5.82% | $150.74M | 2025 Q4 |
| AMZN | 562,559 | $230.82 | Increased | 0.10% | 5.01% | $129.85M | 2025 Q4 |
| RPRX | 3,333,675 | $38.64 | Increased | 6.92% | 4.97% | $128.81M | 2025 Q4 |
| QXO | 6,468,854 | $19.29 | Reduced | -1.04% | 4.82% | $124.78M | 2025 Q4 |
| UNH | 368,293 | $330.11 | Reduced | -0.83% | 4.69% | $121.58M | 2025 Q4 |
| NVDA | 638,814 | $186.5 | Increased | 0.97% | 4.60% | $119.14M | 2025 Q4 |
| NCLH | 5,308,128 | $22.32 | Increased | 16.28% | 4.57% | $118.48M | 2025 Q4 |
| BIIB | 576,352 | $175.99 | Increased | 45.31% | 3.92% | $101.43M | 2025 Q4 |
| CVS | 1,231,416 | $79.36 | Reduced | -0.68% | 3.77% | $97.73M | 2025 Q4 |
| META | 143,094 | $660.09 | Reduced | -0.63% | 3.65% | $94.45M | 2025 Q4 |
| IAC | 2,374,050 | $39.1 | Increased | 12.61% | 3.58% | $92.83M | 2025 Q4 |
| ET | 5,272,875 | $16.49 | Increased | 7.87% | 3.36% | $86.95M | 2025 Q4 |
| PGEN | 18,673,466 | $4.18 | Reduced | -29.43% | 3.01% | $78.06M | 2025 Q4 |
| ILMN | 575,768 | $131.16 | Reduced | -0.96% | 2.92% | $75.52M | 2025 Q4 |
| UAL | 654,121 | $111.82 | Reduced | -1.86% | 2.82% | $73.14M | 2025 Q4 |
| SDRL | 2,053,797 | $34.6 | Reduced | -7.90% | 2.74% | $71.06M | 2025 Q4 |
| CROX | 758,797 | $85.52 | Increased | 28.87% | 2.51% | $64.89M | 2025 Q4 |
| GM | 771,647 | $81.32 | Reduced | -17.96% | 2.42% | $62.75M | 2025 Q4 |
| FBTC | 781,695 | $76.23 | Increased | 26.13% | 2.30% | $59.59M | 2025 Q4 |
| OMF | 824,942 | $67.55 | Reduced | -11.95% | 2.15% | $55.72M | 2025 Q4 |
| MAT | 2,794,343 | $19.84 | Increased | 33.11% | 2.14% | $55.44M | 2025 Q4 |
| UBS | 1,187,326 | $46.31 | Reduced | -20.89% | 2.12% | $54.99M | 2025 Q4 |
| CHYM | 2,035,112 | $25.17 | Buy | 100.00% | 1.98% | $51.22M | 2025 Q4 |
| EXPE | 176,282 | $283.31 | Reduced | -30.45% | 1.93% | $49.94M | 2025 Q4 |